Drug Response Profiling for Systems Medicine
Apricot BIO’s platform revolutionizes cancer treatment by capturing the deep molecular phenotype of single cells in response to anti-cancer drugs – An assay we term 4i Drug Response Profiling (4iDRP). This functional response data enables recommendation of the most efficient drug for every individual patient.
ABOUT US
Apricot BIO is pioneering a new era in personalized medicine by mapping the deep single-cell molecular phenotype of drug responses.
Our breakthrough concept – 4i Drug Response Profiling (4iDRP) – measures how single cells from patient biopsies respond to a panel of drugs across a comprehensive set of disease-relevant biomarkers in an image-based approach.
These deep phenotypic single-cell profiles allow us to identify the most potent drug for a given patient in 5 to 7 days, bringing more effective therapies to patients battling cancer and other diseases and unlocking alternative therapies.
OUR PLATFORM
Our Platform utilizes advanced image-based systems biology to perform deep molecular phenotyping of drug responses.
OUR MISSION
Cancer remains the number one cause of death and is one of the heaviest healthcare burdens in Europe and the USA
First generation personalized therapies have had a positive impact on cancer treatments. However, there remains a large population of patients who are not eligible or show limited response to current therapy options.
At Apricot BIO, we are determined to change this picture. Our functional precision oncology platform aims to clear the path to the optimal treatment for every single patient, tailored to their unique cancer phenotype. We focus on providing personalized treatment recommendations for all patients in need.
OUR VISION
Apricot BIO’s goal is to help patients today, but we are also committed to building for the future. Over time, we will amass a data resource of single-cell, deep phenotypic drug response profiles from a diverse cohort of cancer patients. Rich datasets like these will enable the development of cutting-edge deep learning models and discovery tools, including:
Deep Learning Models to Predict Drug Combination Outcomes
01
Cohort Stratification for Clinical Trial Design
02
Biomarker Discovery
03
Cancer Vulnerability Discovery
04
Lead Compound Profiling in Drug Development
05
LATEST NEWS
Apricot BIO signed its first proof-of-concept partnership agreement to generate a unique dataset for the characterization of novel compounds that target previously thought undruggable proteins involved in cancer.
First proof-of-concept partner signed
18 December 2022
4i platform enables spatial multi-omics on tissue sections
Apricot BIO signed its first proof-of-concept partnership agreement to generate a unique dataset for the characterization of novel compounds that target previously thought undruggable proteins involved in cancer.
8 May 2023
Apricot BIO signed its first proof-of-concept partnership agreement to generate a unique dataset for the characterization of novel compounds that target previously thought undruggable proteins involved in cancer.
First proof-of-concept partner signed
18 December 2022
Get in touch with us
Are you interested in working with us? Please fill out the form and we will get back to you shortly. We look forward to hearing from you.